Search

Tomas Mikael Mustelin

from Seattle, WA
Age ~65

Tomas Mustelin Phones & Addresses

  • 3223 Perkins Ln W, Seattle, WA 98199 (206) 473-7883
  • Rockville, MD
  • Easton, WA
  • 11308 Caminito Aclara, San Diego, CA 92126 (858) 635-6760
  • 13261 Deer Canyon Pl, San Diego, CA 92129 (858) 484-6523
  • Kittitas, WA
  • 11904 Tallwood Ct, Potomac, MD 20854 (206) 420-2036

Work

Company: Medimmune Jul 2012 Position: Interim head of research

Education

Degree: PhD School / High School: Helsingin yliopisto 1985 to 1987 Specialities: Signal Transduction

Skills

Immunology • Drug Discovery • Biotechnology • Drug Development • Cell Biology • Cancer • Translational Research • Signal Transduction • Clinical Trials • Genomics • Genetics • Molecular Biology • Inflammation • Biomarkers • Lifesciences • Cell Signaling • Clinical Research • Cell • Biochemistry • Biopharmaceuticals • Cell Culture • In Vivo • Antibodies • Translational Medicine • Animal Models • Protein Chemistry • Protein Expression • In Vitro • Infectious Diseases • High Throughput Screening • Protein Purification • Assay Development • Monoclonal Antibodies • Flow Cytometry • Immunohistochemistry • Therapists • Clinical Development • Oncology • Tissue Culture • Pharmacology • Elisa • Vaccines • Therapeutics • Cancer Research • Neuroscience • Virology • Western Blotting • Immunoassays • Immunoprecipitation • Toxicology

Industries

Biotechnology

Resumes

Resumes

Tomas Mustelin Photo 1

Professor Of Medicine

View page
Location:
Washington, DC
Industry:
Biotechnology
Work:
Medimmune since Jul 2012
Interim Head of Research

MedImmune - Gaithersburg, MD since Jan 2012
Vice President Research, Respiratory, Inflammatory, and Autoimmune diseases

UC San Diego since 2011
Member of the UCSD Clinical and Translational Research Institute (CTRI)

Burnham Institute since 2007
Adjunct Professor

UCSD since Jun 2007
Adjunct Professor
Education:
Helsingin yliopisto 1985 - 1987
PhD, Signal Transduction
Helsingin yliopisto 1981 - 1987
MD, Medicine
Skills:
Immunology
Drug Discovery
Biotechnology
Drug Development
Cell Biology
Cancer
Translational Research
Signal Transduction
Clinical Trials
Genomics
Genetics
Molecular Biology
Inflammation
Biomarkers
Lifesciences
Cell Signaling
Clinical Research
Cell
Biochemistry
Biopharmaceuticals
Cell Culture
In Vivo
Antibodies
Translational Medicine
Animal Models
Protein Chemistry
Protein Expression
In Vitro
Infectious Diseases
High Throughput Screening
Protein Purification
Assay Development
Monoclonal Antibodies
Flow Cytometry
Immunohistochemistry
Therapists
Clinical Development
Oncology
Tissue Culture
Pharmacology
Elisa
Vaccines
Therapeutics
Cancer Research
Neuroscience
Virology
Western Blotting
Immunoassays
Immunoprecipitation
Toxicology

Publications

Us Patents

Functional Variant Of Lymphoid Tyrosine Phosphatase Is Associated With Autoimmune Disorders

View page
US Patent:
20080199514, Aug 21, 2008
Filed:
Jul 11, 2005
Appl. No.:
11/571711
Inventors:
Tomas Mikael Mustelin - San Diego CA, US
Nunzio Bottini - Pasadena CA, US
Assignee:
THE BURNHAM INSTITUTE - La Jolla CA
International Classification:
C12Q 1/42
C12Q 1/68
G01N 33/50
A61K 31/70
A61K 39/395
C12N 9/16
C12N 15/52
A61K 31/7088
A61K 9/127
A61K 38/02
C12Q 1/02
US Classification:
424450, 435 6, 435 29, 435 21, 435 71, 435 792, 514 2, 514 23, 4241301, 514 44, 435196, 536 232
Abstract:
The invention is the discovery of a single nucleotide polymorphism in the gene coding for lymphoid tyrosine phosphatase. This SNP leads to a mutation in the lymphoid tyrosine phosphatase protein that prohibits binding with the SH3 domain of Csk, and leads to a subsequent dysregulation of the T-Cell activation cascade. Such dysregulation can lead to a variety of autoimmune disorders. Thus, the invention provides a series of useful methods for diagnosing, discovering modulators, developing treatments and providing research tools. Also, the invention provides compositions of matter useful for research and useful for the diagnosis and treatment of these disorders.

Methods For Treating Leukemia And Myelodysplastic Syndrome, And Methods For Identifying Agents For Treating Same

View page
US Patent:
20090105240, Apr 23, 2009
Filed:
Oct 17, 2007
Appl. No.:
11/975082
Inventors:
Tomas Mustelin - Seattle WA, US
Lutz Tautz - La Jolla CA, US
Nicholas David Peter Cosford - La Jolla CA, US
Eduard Sergienko - La Jolla CA, US
International Classification:
A61K 31/53
A61K 31/47
A61K 31/435
A61K 31/453
A61K 31/5377
A61P 35/02
C12Q 1/42
A61K 31/433
A61K 31/42
A61K 31/439
US Classification:
5142315, 514312, 514290, 514326, 514363, 514380, 514304, 514242, 435 21
Abstract:
The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

Vhr Protein Tyrosine Phosphatase Inhibitors, Compositions And Methods Of Use

View page
US Patent:
20090105254, Apr 23, 2009
Filed:
Oct 17, 2008
Appl. No.:
12/253804
Inventors:
Tomas Mustelin - La Jolla CA, US
Lutz Tautz - La Jolla CA, US
Assignee:
BURNHAM INSTITUTE FOR MEDICAL RESEARCH - La Jolla CA
International Classification:
A61K 31/427
A61P 35/00
C07D 417/06
A61K 31/5377
A61K 31/454
A61K 31/426
US Classification:
5142365, 548183, 514369, 514326
Abstract:
Disclosed herein are H1-related (VHR) protein tyrosine phosphatase (PTP) inhibitors that provide a method for treating cancer.

Compositions And Methods For Treatment Of Disease Caused By Yersinia Spp Infection

View page
US Patent:
20090312352, Dec 17, 2009
Filed:
Oct 19, 2005
Appl. No.:
11/577591
Inventors:
Tomas Mikael Mustelin - La Jolla CA, US
Maurizio Pellecchia - La Jolla CA, US
Lutz Tautz - La Jolla CA, US
International Classification:
A61K 31/506
C07D 405/06
C07D 417/14
A61K 31/429
A61K 31/41
C07D 405/12
C07D 307/02
A61K 31/341
A61K 31/4196
A61K 31/427
A61P 31/10
US Classification:
514274, 544300, 548151, 514366, 514382, 548253, 549501, 514461, 514383, 5482648, 548183, 514369
Abstract:
The invention generally relates to compositions and methods for treatment of disease caused by spp. infection. More specifically, the invention relates to protein tyrosine phosphatase inhibitors and derivatives and analogs thereof, pharmaceutical compositions containing the protein tyrosine phosphatase inhibitors and analogs, methods of making the protein tyrosine phosphatase inhibitors and analogs and methods of use thereof.

Ang-2 Inhibition To Treat Multiple Sclerosis

View page
US Patent:
20110158978, Jun 30, 2011
Filed:
Dec 23, 2010
Appl. No.:
12/977991
Inventors:
Jacqueline A. Kirchner - Seattle WA, US
Tomas Mikael Mustelin - Seattle WA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 39/395
A61P 25/28
US Classification:
4241301
Abstract:
Methods and compositions are disclosed for treating multiple sclerosis in a human subject by administering a therapeutically effective amount of an H4L4 antibody or a 2XCon4(C) peptibody.

Methods For Treating Leukemia And Myelodysplastic Syndrome, And Methods For Identifying Agents For Treating Same

View page
US Patent:
20120095032, Apr 19, 2012
Filed:
Dec 6, 2011
Appl. No.:
13/312391
Inventors:
Tomas Mustelin - Seattle WA, US
Lutz Tautz - San Diego CA, US
Nicolas David Peter Cosford - San Diego CA, US
Eduard Sergienko - San Diego CA, US
International Classification:
A61K 31/437
C12N 5/10
C12N 5/071
A61P 35/02
A61P 7/00
US Classification:
514293, 435375
Abstract:
The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.

Novel Il33 Form, Mutated Forms Of Il33, Antibodies, Assays And Methods Of Using The Same

View page
US Patent:
20200353078, Nov 12, 2020
Filed:
Apr 10, 2020
Appl. No.:
16/845121
Inventors:
Emma S. Cohen - Cambridge, GB
David C. Lowe - Cambridge, GB
Robin Butler - Cambridge, GB
Ian C. Scott - Cambridge, GB
Katherine A. Vousden - Cambridge, GB
Martin D. Strain - Cambridge, GB
Sara Carmen - Cambridge, GB
Elizabeth H. England - Cambridge, GB
Benjamin P. Kemp - Cambridge, GB
David G. Rees - Cambridge, GB
Catherine L. Overed-Sayer - Cambridge, GB
Tomas M. Mustelin - Gaithersburg MD, US
Matthew Sleeman - Cambridge, GB
Kirsty Houslay - Cambridge, GB
International Classification:
A61K 39/395
C07K 16/24
A01K 67/027
C07K 14/54
A61P 11/06
Abstract:
The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

Anti-Pad4 Autoantibodies As Clinical Response Biomarkers For The Treatment Of Rheumatoid Arthritis

View page
US Patent:
20200317793, Oct 8, 2020
Filed:
May 23, 2017
Appl. No.:
16/304055
Inventors:
- Cambridge, Cambridgeshire, GB
Alex GODWOOD - Cambridge, GB
Ethan Paul GRANT - Gaithersburg MD, US
Martin Michael Kari SCHWICKART - Gaithersburg MD, US
Carlos CHAVEZ - Gaithersburg MD, US
Meina LIANG - Gaithersburg MD, US
Tomas Mikael MUSTELIN - Seattle WA, US
Zhengbin YAO - Gaithersburg MD, US
Koustubh RANADE - Gaithersburg MD, US
International Classification:
C07K 16/28
G01N 33/68
G01N 33/564
Abstract:
The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
Tomas Mikael Mustelin from Seattle, WA, age ~65 Get Report